Key result
Ticagrelor cuts major events ~23% vs clopidogrel in ACS patients with CKD.
Why the study?
Reduced renal function in ACS is associated with poorer prognosis and higher bleeding risk, potentially altering the risk-benefit ratio of antiplatelet therapies.
Does ticagrelor reduce the composite of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in patients with acute coronary syndromes and chronic kidney disease?
RCT (n=15,202)
Yes
Does ticagrelor reduce the composite of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in patients with acute coronary syndromes and chronic kidney disease?
Ticagrelor provides a significant reduction in ischemic endpoints and mortality compared to clopidogrel in ACS patients with chronic kidney disease, without a significant increase in major bleeding.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A large proportion of patients with MI also have kidney disease and these results show that ticagrelor, as compared to clopidogrel, was associated with significantly lower risk of ischaemic outcomes in patients with moderate renal dysfunction.”
“Despite the increased risk for adverse outcomes, CKD patients presenting with ACS are less likely to receive evidence-based therapies, including medications. In addition, patients with CKD have been under represented in randomized controlled trials of ACS pharmacotherapy.”
“The fear of bleeding is a real concern. The worry is that they'll bleed, stop the dual antiplatelet therapy, and then they'll have more problems. It's something that's obviously of major concern.”
Supports ticagrelor over clopidogrel in ACS with CKD; extends PLATO benefits to this high-risk subgroup.
BACKGROUND: Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-benefit ratio with antiplatelet therapies. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor compared with clopidogrel reduced the primary composite end point of cardiovascular death, myocardial infarction, and stroke at 12 months but with similar major bleeding rates. METHODS AND RESULTS: Central laboratory serum creatinine levels were available in 15 202 (81.9%) acute coronary syndrome patients at baseline, and creatinine clearance, estimated by the Cockcroft Gault equation, was calculated. In patients with chronic kidney disease (creatinine clearance <60 mL/min; n=3237), ticagrelor versus clopidogrel significantly reduced the primary end point to 17.3% from 22.0% (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.65 to 0.90) with an absolute risk reduction greater than that of patients with normal renal function (n=11 965): 7.9% versus 8.9% (HR, 0.90; 95% CI, 0.79 to 1.02). In patients with chronic kidney disease, ticagrelor reduced total mortality (10.0% versus 14.0%; HR, 0.72; 95% CI, 0.58 to 0.89). Major bleeding rates, fatal bleedings, and non-coronary bypass-related major bleedings were not significantly different between the 2 randomized groups (15.1% versus 14.3%; HR, 1.07; 95% CI, 0.88 to 1.30; 0.34% versus 0.77%; HR, 0.48; 95% CI, 0.15 to 1.54; and 8.5% versus 7.3%; HR, 1.28; 95% CI, 0.97 to 1.68). The interactions between creatinine clearance and randomized treatment on any of the outcome variables were nonsignificant. CONCLUSIONS: In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding. CLINICAL TRIAL REGISTRATION: URL:http://www.clinicatrials.gov. Unique identifier: NCT00391872.
No takes yet. Share an insight, caveat, or question.
James et al. (2010) conducted an RCT in Acute coronary syndromes (n=15,202). Ticagrelor vs. Clopidogrel was evaluated on Composite of cardiovascular death, myocardial infarction, and stroke in patients with chronic kidney disease (HR 0.77, 95% CI 0.65 to 0.90). In ACS patients with chronic kidney disease, ticagrelor reduced cardiovascular death, MI, and stroke compared with clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: